Active-ingredient Dossier
Gemcitabine Hydrochloride
Active-ingredient Dossier for Gemcitabine Hydrochloride (nucleoside metabolic inhibitor). Australian brands, products, PBS listings, PBAC outcomes —…
- Brand: GEMCITABINE
- Brand: GEMCITABINE
- Brand: GEMICITABINE
- Brand: GEMCITABINE
- Brand: GEMCITABINE HETERO
- Brand: Gemcitabine IV Infusion
- Therapeutic area: Oncology
What is
Gemcitabine Hydrochloride Gemcitabine Hydrochloride is a nucleoside metabolic inhibitor.
Australian brands containing
Gemcitabine Hydrochloride — GEMCITABINE AN — GEMCITABINE SANDOZ — GEMACCORD — GEMCITABINE HETERO
Therapeutic areas
Gemcitabine Hydrochloride is registered in oncology (10 brands) and complementary medicine (1 brand).
Sponsor landscape
The ingredient is marketed by Hetero, KSJ Pharmatech, Accord Healthcare, Eugia Pharma, MedTAS and Juno Pharmaceuticals.
PBS and regulatory activity
One brand containing gemcitabine hydrochloride is PBS-listed, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is 1 March 2025.